Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 2;4(5):101025. doi: 10.1016/j.xcrm.2023.101025

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

OS and PFS are significantly improved by ChemoID-guided therapy

(A) Prespecified interim efficacy analysis of OS. The number of events; median OS; OS rates at 0, 6, 12, and 18 months; and the Kaplan-Meier curve for OS in all patients treated with ChemoID-guided (blue) vs. physician-choice (red) therapies. Symbols, censored observations.

(B) Prespecified interim efficacy analysis of PFS. The number of events; median PFS; PFS rates at 0, 6, 12, and 18 months; and the Kaplan-Meier curve for PFS per investigator assessment in patients treated with ChemoID-guided (blue) vs. physician-choice (red) therapies. Symbols indicate censored observations.

(C) Intention-to-treat analysis of OS. The number of events; median OS; OS rates at 0, 6, 12, and 18 months; and the Kaplan-Meier curve for OS in all patients treated with ChemoID-guided (blue) vs. physician-choice (red) therapies. Symbols, censored observations.

(D) Intention-to-treat Analysis of PFS. The number of events; median PFS; PFS rates at 0, 6, 12, and 18 months; and the Kaplan-Meier curve for PFS per investigator assessment in patients treated with ChemoID-guided (blue) vs. physician-choice (red) therapies. Symbols indicate censored observations. A Cox proportional hazards model estimated hazard ratios (HRs) and CIs.